

Table of Contents

ABBREVIATIONS	IX
CHAPTER 1. SUMMARY OF IARC/NCI EXPERT MEETING ON PRIMARY END-POINTS FOR PROPHYLACTIC HPV VACCINE TRIALS	1
1.1 EXECUTIVE SUMMARY	1
1.2 BACKGROUND	2
1.3 RATIONALE FOR THE IARC/NCI EXPERT MEETING ON PRIMARY END-POINTS FOR PROPHYLACTIC HPV VACCINE TRIALS	4
1.4 EXPERT MEETING ON PRIMARY END-POINTS FOR PROPHYLACTIC HPV VACCINE TRIALS.....	5
1.5 RECOMMENDATIONS OF VACCINE END-POINTS	9
REFERENCES	11
CHAPTER 2. NEXT-GENERATION HPV VACCINES – POTENTIAL FOR ALTERNATIVE END-POINTS	21
2.1 INTRODUCTION	21
2.2 LICENSED PROPHYLACTIC HPV VACCINES.....	21
2.3 NEXT-GENERATION VACCINES.....	22
2.4 VACCINE END-POINTS.....	23
2.5 NATURAL HISTORY OF HPV INFECTION IN THE GENITAL TRACT	23
2.6 PERSISTENT INFECTION AS A SURROGATE END-POINT FOR HIGH-GRADE CERVICAL DISEASE .	24
2.7 VACCINE-INDUCED IMMUNE RESPONSES	30
2.8 MONITORING VACCINE-INDUCED IMMUNITY – SERO-ASSAYS	30
2.9 IMMUNOGENICITY	31
2.10 IMMUNOGENICITY AND SECOND-GENERATION VACCINES	32
REFERENCES	32
CHAPTER 3. METHODOLOGICAL ISSUES FOR TRIALS OF VACCINE EFFICACY AGAINST HPV TYPES 16 AND 18.....	39
3.1 INTRODUCTION	39
3.2 VALIDATED AND NON-VALIDATED END-POINTS	39
3.3 ARE RANDOMIZED CONTROLLED TRIALS WITH CIN2/3 END-POINTS FEASIBLE FOR THE FUTURE GENERATION OF HPV VACCINES?.....	42
3.4 BENCHMARKING PROTECTION AGAINST HPV 16 AND 18	43
3.5 CONCLUSIONS	45
REFERENCES	45
CHAPTER 4. TRIALS OF VACCINE EFFICACY AGAINST CERVICAL OUTCOMES ASSOCIATED WITH HPV TYPES OTHER THAN HPV 16 AND 18.....	47
4.1 INTRODUCTION	47
4.2 MAIN OPEN ISSUES	48
4.3 DISCUSSION	50

REFERENCES	51
CHAPTER 5. EVALUATION OF DURABILITY OF PROTECTION OF HPV PROPHYLACTIC VACCINES	56
5.1 INTRODUCTION	56
5.2 DURABILITY OF PROTECTION.....	56
5.3 CENTRAL QUESTIONS.....	57
5.4 CONCLUSIONS	59
REFERENCES	60
CHAPTER 6. HPV VLP VACCINES – ALTERNATIVE DOSAGE SCHEDULES AND IMMUNIZATION IN IMMUNOSUPPRESSED SUBJECTS	62
6.1 HPV VACCINES.....	62
6.2 HPV VACCINATION PROGRAMMES	62
6.3 ALTERNATIVE DOSING SCHEDULES: MODIFIED THREE-DOSE SCHEDULES	62
6.4 ALTERNATIVE DOSING SCHEDULES: REDUCTION FROM THREE TO TWO DOSES	63
6.5 VACCINE IMMUNOGENICITY: LICENSED THREE-DOSE REGIMENS	64
6.6 RANDOMIZED CONTROLLED TRIALS OF ALTERNATIVE DOSAGE SCHEDULES.....	64
6.7 EFFICACY OF TWO-DOSE VERSUS THREE-DOSE SCHEDULES	67
6.8 GLOBAL EXPERIENCE: USE OF OFF-LICENCE DOSING SCHEDULES	67
6.9 UNRESOLVED ISSUES.....	67
6.10 MEMORY B CELLS	68
6.11 IMMUNIZATION SCHEDULES IN IMMUNOSUPPRESSED SUBJECTS.....	69
REFERENCES	70
CHAPTER 7. TRIALS OF VACCINE EFFICACY AGAINST NON-CERVICAL OUTCOMES – PREVENTION OF ANAL HPV INFECTION AND ANAL CANCER.....	76
7.1 INTRODUCTION	76
7.2 ANAL CANCER AND CERVICAL CANCER SHARE A SIMILAR ASSOCIATION WITH HPV	76
7.3 THE ASSOCIATION BETWEEN HPV INFECTION AND ANAL CANCER IS SIMILAR IN MEN AND WOMEN.....	77
7.4 ANAL HSIL IS THE PRECURSOR TO ANAL CANCER	78
7.5 HIGH-RISK ANAL HPV INFECTION IS ASSOCIATED WITH HSIL, AND THE ASSOCIATION IS SIMILAR IN MEN AND WOMEN	78
7.6 ROUTES OF ANAL HPV INFECTION MAY DIFFER BETWEEN MEN AND WOMEN BUT DO NOT HAVE AN IMPACT ON CONSIDERATION OF BIOMARKERS OF VACCINE EFFICACY.....	79
7.7 NATURAL HISTORY OF ANAL HPV INFECTION MAY DIFFER BETWEEN MEN AND WOMEN BUT DOES NOT HAVE AN IMPACT ON CONSIDERATION OF BIOMARKERS OF VACCINE EFFICACY	79
7.8 HPV INFECTION AS A BIOMARKER OF THE EFFICACY OF HPV VACCINATION TO PREVENT INCIDENT ANAL HSIL AMONG INDIVIDUALS OLDER THAN 26 YEARS	81
7.9 HPV AS A BIOMARKER OF THE EFFICACY OF HPV VACCINATION AS A TOOL TO PREVENT RECURRENT DISEASE AFTER TREATMENT OF ANAL HSIL	81
7.10 CONCLUSIONS	81
REFERENCES	82

CHAPTER 8. HPV VACCINES AND POTENTIAL PREVENTION OF HPV-POSITIVE HEAD AND NECK CANCER	86
8.1 INTRODUCTION	86
8.2 HPV ETIOLOGY OF CERVICAL VERSUS OROPHARYNGEAL CANCERS.....	86
8.3 SEX-BASED DIFFERENCES IN INCIDENCE OF HPV-POSITIVE OROPHARYNGEAL CANCERS	87
8.4 SEX-BASED DIFFERENCES IN NATURAL HISTORY OF ORAL HPV INFECTION	87
8.5 HISTOPATHOLOGICAL PROGRESSION OF CERVICAL CANCER VERSUS OROPHARYNGEAL CANCER	88
8.6 PREVENTION OF ORAL HPV INFECTION AND ASSOCIATED CANCERS	88
REFERENCES	90
DISCLOSURES OF INTERESTS	93

TABLES

Table 1.1 End-points for placebo-controlled trial of a licensed HPV VLP vaccine: three doses	14
Table 1.2 End-points for development of a new HPV VLP vaccine similar to a licensed product or products: three doses	15
Table 1.3 End-points for development of a new polyvalent VLP vaccine containing additional HPV types compared with a licensed product or products: three doses	16
Table 1.4 End-points for one or two doses for an HPV VLP vaccine approved for three doses, for situations in which immunological non-inferiority can be demonstrated	17
Table 1.5 End-points for one or two doses for an HPV VLP vaccine approved for three doses: alternative approach for situations in which immunologic non-inferiority cannot be demonstrated	18
Table 1.6 End-points for cross-protection against non-vaccine types for any VLP vaccine.....	19
Table 1.7 End-points for non-VLP vaccines.....	20
Table 2.1 Vaccine efficacy against high-grade cervical lesions associated with HPV 16/18 (according-to-protocol [ATP] cohort) in the PATRICIA trial	27
Table 2.2 Vaccine efficacy against virological end-points associated with HPV 16/18 (according-to-protocol [ATP] cohort) in the PATRICIA trial	27
Table 2.3 Studies of the quadrivalent HPV (qHPV) vaccine in women that assessed persistent infection	28
Table 2.4 HPV 16/18-related CIN2 or worse by prior infection with the same HPV type (subjects naive to the relevant type receiving placebo)	29
Table 3.1 End-points based on HPV 16 and 18 virological and lesion frequencies in the placebo arm of the Costa Rica Vaccine Trial and associated sample size requirements.....	43
Table 4.1 Main questions and answers in relation to vaccine end-points associated with HPV types other than HPV 16 and 18	48
Table 4.2 Prevalence rate of HPV 16 and other high-risk HPV types (X) as a percentage of HPV-positive women, in CIN2 and CIN3	54
Table 4.3 Effect of selection of end-point on vaccine efficacy against (i) HPV 31/33/45, (ii) other non-HPV 16/18 carcinogenic HPV types, and (iii) all carcinogenic HPV types, in an according-to-protocol (ATP) analytic cohort.....	55